| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 28 | 2022 | 266 | 5.020 |
Why?
|
| Interleukin-15 | 16 | 2022 | 66 | 3.940 |
Why?
|
| Interleukin-2 | 9 | 2018 | 133 | 2.490 |
Why?
|
| Neoplasms | 16 | 2023 | 1667 | 1.910 |
Why?
|
| Interleukin-12 | 7 | 2016 | 75 | 1.650 |
Why?
|
| Adoptive Transfer | 10 | 2018 | 100 | 1.620 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2022 | 132 | 1.450 |
Why?
|
| Interleukin-7 | 5 | 2017 | 18 | 1.440 |
Why?
|
| Immunotherapy | 7 | 2022 | 215 | 1.430 |
Why?
|
| Melanoma | 8 | 2022 | 335 | 1.290 |
Why?
|
| Mice, Inbred C57BL | 26 | 2022 | 2791 | 0.990 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2021 | 66 | 0.950 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2019 | 135 | 0.890 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2015 | 126 | 0.860 |
Why?
|
| Lymphocyte Activation | 12 | 2019 | 397 | 0.860 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 12 | 0.820 |
Why?
|
| Mice | 36 | 2022 | 8474 | 0.820 |
Why?
|
| Melanoma, Experimental | 4 | 2017 | 95 | 0.790 |
Why?
|
| T-Lymphocytes | 7 | 2020 | 597 | 0.760 |
Why?
|
| Transduction, Genetic | 3 | 2015 | 81 | 0.740 |
Why?
|
| Th17 Cells | 3 | 2020 | 116 | 0.730 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 4 | 2019 | 10 | 0.720 |
Why?
|
| Animals | 43 | 2022 | 20881 | 0.710 |
Why?
|
| Proteins | 3 | 2018 | 474 | 0.660 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2017 | 7 | 0.660 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2015 | 32 | 0.610 |
Why?
|
| Cell Line, Tumor | 11 | 2019 | 1851 | 0.600 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 511 | 0.600 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 74 | 0.570 |
Why?
|
| Moloney murine leukemia virus | 2 | 2015 | 13 | 0.570 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2022 | 376 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 300 | 0.530 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2015 | 6 | 0.520 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 9 | 0.520 |
Why?
|
| Myeloid Cells | 2 | 2013 | 57 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 468 | 0.490 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 6 | 2021 | 91 | 0.450 |
Why?
|
| Immunoconjugates | 1 | 2013 | 26 | 0.450 |
Why?
|
| Humans | 53 | 2023 | 68618 | 0.450 |
Why?
|
| Mice, Transgenic | 12 | 2019 | 1033 | 0.430 |
Why?
|
| Killer Cells, Natural | 4 | 2019 | 94 | 0.400 |
Why?
|
| Tumor Microenvironment | 7 | 2022 | 213 | 0.400 |
Why?
|
| Apoptosis | 5 | 2017 | 1641 | 0.400 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 110 | 0.390 |
Why?
|
| Cell Proliferation | 10 | 2017 | 1174 | 0.380 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2022 | 87 | 0.380 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2008 | 42 | 0.370 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 375 | 0.370 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2019 | 199 | 0.350 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2020 | 226 | 0.350 |
Why?
|
| Receptors, Interleukin-15 | 4 | 2013 | 7 | 0.340 |
Why?
|
| Mice, Knockout | 6 | 2016 | 1692 | 0.340 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1173 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2013 | 66 | 0.330 |
Why?
|
| Retroviridae | 1 | 2008 | 29 | 0.320 |
Why?
|
| Cyclophosphamide | 3 | 2016 | 129 | 0.300 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 332 | 0.290 |
Why?
|
| Immunologic Memory | 8 | 2016 | 75 | 0.290 |
Why?
|
| Contact Lenses | 2 | 2003 | 14 | 0.290 |
Why?
|
| Lymphocyte Depletion | 2 | 2018 | 34 | 0.280 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2003 | 29 | 0.270 |
Why?
|
| Cells, Cultured | 6 | 2016 | 2673 | 0.260 |
Why?
|
| Protein Isoforms | 1 | 2006 | 246 | 0.260 |
Why?
|
| Cancer Vaccines | 3 | 2017 | 61 | 0.250 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 561 | 0.250 |
Why?
|
| Corneal Diseases | 1 | 2003 | 12 | 0.230 |
Why?
|
| Antibody Formation | 1 | 2023 | 93 | 0.210 |
Why?
|
| Female | 21 | 2022 | 38074 | 0.210 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 329 | 0.210 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 17 | 0.200 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 30 | 0.200 |
Why?
|
| Eyeglasses | 2 | 2000 | 11 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.200 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 78 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.200 |
Why?
|
| Cytokines | 4 | 2020 | 866 | 0.190 |
Why?
|
| Dendritic Cells | 4 | 2017 | 201 | 0.190 |
Why?
|
| Amblyopia | 3 | 1991 | 43 | 0.190 |
Why?
|
| Interleukin-17 | 3 | 2016 | 62 | 0.190 |
Why?
|
| Recombinant Proteins | 5 | 2019 | 742 | 0.190 |
Why?
|
| Immunity, Cellular | 2 | 2021 | 80 | 0.180 |
Why?
|
| Vision, Low | 1 | 2000 | 5 | 0.180 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 8 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 18 | 0.180 |
Why?
|
| Gene Expression | 3 | 2021 | 770 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 163 | 0.180 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2020 | 14 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 19 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 800 | 0.170 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.170 |
Why?
|
| Thrombin | 1 | 2020 | 117 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 45 | 0.170 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 206 | 0.170 |
Why?
|
| Male | 16 | 2022 | 37321 | 0.170 |
Why?
|
| Thioredoxins | 1 | 2019 | 26 | 0.170 |
Why?
|
| Flow Cytometry | 4 | 2016 | 489 | 0.170 |
Why?
|
| Prostheses and Implants | 1 | 2000 | 159 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.160 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 2 | 2016 | 9 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 299 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2016 | 79 | 0.150 |
Why?
|
| Ovalbumin | 3 | 2008 | 33 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7029 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1070 | 0.150 |
Why?
|
| Polylysine | 1 | 2017 | 13 | 0.150 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 7 | 0.150 |
Why?
|
| Poly I-C | 1 | 2017 | 20 | 0.140 |
Why?
|
| Aged | 9 | 2021 | 14862 | 0.140 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2003 | 5 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 629 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 40 | 0.140 |
Why?
|
| Rituximab | 1 | 2016 | 61 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2016 | 132 | 0.130 |
Why?
|
| Vaccines, Subunit | 2 | 2007 | 10 | 0.130 |
Why?
|
| Cell Survival | 2 | 2008 | 901 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 189 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2020 | 617 | 0.130 |
Why?
|
| Neutrophils | 1 | 2016 | 204 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 63 | 0.130 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.130 |
Why?
|
| Visual Acuity | 7 | 2000 | 236 | 0.120 |
Why?
|
| Genetic Vectors | 2 | 2008 | 312 | 0.120 |
Why?
|
| Middle Aged | 9 | 2021 | 21147 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 148 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 268 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 756 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 411 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 2550 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2015 | 2689 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 92 | 0.100 |
Why?
|
| Phenotype | 4 | 2021 | 947 | 0.100 |
Why?
|
| Cornea | 3 | 1991 | 76 | 0.100 |
Why?
|
| Scotoma | 1 | 1991 | 4 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1293 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2015 | 753 | 0.090 |
Why?
|
| Fixation, Ocular | 1 | 1991 | 13 | 0.090 |
Why?
|
| Vision Disorders | 1 | 1991 | 94 | 0.090 |
Why?
|
| Evoked Potentials | 2 | 1981 | 61 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 1 | 2010 | 67 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1034 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2007 | 38 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 514 | 0.090 |
Why?
|
| Protein Binding | 2 | 2020 | 1027 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 71 | 0.090 |
Why?
|
| Intellectual Disability | 1 | 1991 | 114 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2010 | 114 | 0.090 |
Why?
|
| Antigens | 2 | 2007 | 90 | 0.090 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 1990 | 110 | 0.080 |
Why?
|
| Anisometropia | 1 | 1989 | 12 | 0.080 |
Why?
|
| United States | 2 | 2018 | 7367 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 1990 | 258 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2013 | 241 | 0.080 |
Why?
|
| Transgenes | 1 | 2008 | 92 | 0.080 |
Why?
|
| Cell Movement | 2 | 2008 | 630 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 226 | 0.080 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2007 | 8 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2007 | 32 | 0.070 |
Why?
|
| Egg Proteins | 2 | 2004 | 15 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2006 | 17 | 0.070 |
Why?
|
| Peptide Fragments | 3 | 2004 | 483 | 0.070 |
Why?
|
| Arthroscopy | 1 | 1987 | 95 | 0.070 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2006 | 62 | 0.070 |
Why?
|
| Photic Stimulation | 3 | 1982 | 229 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 532 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 173 | 0.060 |
Why?
|
| Shoulder Joint | 1 | 1987 | 110 | 0.060 |
Why?
|
| Lenses, Intraocular | 3 | 1991 | 96 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2006 | 235 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 214 | 0.060 |
Why?
|
| Antigen-Antibody Complex | 1 | 2006 | 175 | 0.060 |
Why?
|
| Hospital Departments | 1 | 1984 | 15 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 852 | 0.060 |
Why?
|
| Electroretinography | 2 | 1982 | 122 | 0.060 |
Why?
|
| Ophthalmology | 1 | 1984 | 39 | 0.060 |
Why?
|
| Prosthesis Fitting | 1 | 2003 | 6 | 0.060 |
Why?
|
| Silicone Elastomers | 1 | 2003 | 17 | 0.060 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2003 | 17 | 0.060 |
Why?
|
| Thymoma | 1 | 2003 | 14 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 2003 | 17 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2020 | 330 | 0.060 |
Why?
|
| Optics and Photonics | 3 | 1992 | 29 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2020 | 525 | 0.060 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2003 | 3 | 0.050 |
Why?
|
| CD8 Antigens | 1 | 2003 | 25 | 0.050 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2003 | 5 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2006 | 458 | 0.050 |
Why?
|
| Aging | 1 | 1989 | 911 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 53 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2003 | 76 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1038 | 0.050 |
Why?
|
| Adult | 8 | 2021 | 21403 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Evoked Potentials, Visual | 1 | 1982 | 18 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 20 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 124 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 1864 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 2021 | 29 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2021 | 110 | 0.050 |
Why?
|
| Visual Cortex | 1 | 1981 | 67 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 67 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.050 |
Why?
|
| Visually Impaired Persons | 1 | 2000 | 2 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.050 |
Why?
|
| Brain | 2 | 1982 | 2176 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.040 |
Why?
|
| Depth Perception | 2 | 1991 | 12 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 714 | 0.040 |
Why?
|
| Child | 4 | 2000 | 6405 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 2019 | 24 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2019 | 16 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 18 | 0.040 |
Why?
|
| L-Selectin | 1 | 2019 | 28 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 521 | 0.040 |
Why?
|
| Beijing | 1 | 2018 | 2 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2000 | 189 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 124 | 0.040 |
Why?
|
| China | 1 | 2018 | 138 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2018 | 127 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 489 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 39 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 6 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 1266 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.040 |
Why?
|
| Antioxidants | 1 | 2019 | 304 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 132 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2016 | 29 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 70 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 71 | 0.030 |
Why?
|
| Homeostasis | 2 | 2008 | 291 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 238 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 87 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 2 | 2006 | 50 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 52 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2017 | 1342 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 718 | 0.030 |
Why?
|
| Models, Biological | 2 | 2007 | 981 | 0.030 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 332 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 455 | 0.030 |
Why?
|
| Adolescent | 2 | 2000 | 8912 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2006 | 258 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2000 | 7277 | 0.030 |
Why?
|
| Child, Preschool | 2 | 1991 | 3187 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 2093 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 1992 | 13 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1992 | 33 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2000 | 2800 | 0.020 |
Why?
|
| Community Mental Health Centers | 1 | 1991 | 16 | 0.020 |
Why?
|
| Day Care, Medical | 1 | 1991 | 18 | 0.020 |
Why?
|
| England | 1 | 1991 | 64 | 0.020 |
Why?
|
| Refractive Errors | 1 | 1991 | 24 | 0.020 |
Why?
|
| Aniseikonia | 1 | 1991 | 1 | 0.020 |
Why?
|
| Vision Screening | 1 | 1991 | 40 | 0.020 |
Why?
|
| Inbreeding | 1 | 2010 | 4 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2000 | 4848 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 147 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 92 | 0.020 |
Why?
|
| Polarography | 1 | 1990 | 1 | 0.020 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 1990 | 1 | 0.020 |
Why?
|
| Interferometry | 1 | 1990 | 6 | 0.020 |
Why?
|
| Accommodation, Ocular | 1 | 1990 | 9 | 0.020 |
Why?
|
| Methylmethacrylates | 1 | 1990 | 14 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 1990 | 19 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 201 | 0.020 |
Why?
|
| Lens, Crystalline | 1 | 1990 | 39 | 0.020 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1990 | 39 | 0.020 |
Why?
|
| Monocytes | 1 | 2010 | 210 | 0.020 |
Why?
|
| Epithelium | 1 | 1990 | 172 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1989 | 31 | 0.020 |
Why?
|
| Fluorescein | 1 | 1989 | 15 | 0.020 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 219 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 183 | 0.020 |
Why?
|
| Eye | 1 | 1990 | 89 | 0.020 |
Why?
|
| Electrodes | 1 | 1990 | 147 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Insulinoma | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cataract | 1 | 1990 | 134 | 0.020 |
Why?
|
| Disinfection | 1 | 1989 | 112 | 0.020 |
Why?
|
| Refraction, Ocular | 1 | 1989 | 61 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 166 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2009 | 183 | 0.020 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2007 | 7 | 0.020 |
Why?
|
| Baseball | 1 | 1987 | 6 | 0.020 |
Why?
|
| Refractometry | 3 | 1992 | 23 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2007 | 34 | 0.020 |
Why?
|
| Shoulder Dislocation | 1 | 1987 | 17 | 0.020 |
Why?
|
| Tendons | 1 | 1987 | 45 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2007 | 14 | 0.020 |
Why?
|
| Cell Separation | 1 | 2007 | 132 | 0.020 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2007 | 13 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2007 | 47 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2006 | 2 | 0.020 |
Why?
|
| Immune System Diseases | 1 | 2006 | 12 | 0.020 |
Why?
|
| Athletic Injuries | 1 | 1987 | 73 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2006 | 15 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1990 | 631 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 94 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 101 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 317 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2006 | 45 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 56 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2006 | 69 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 242 | 0.020 |
Why?
|
| Liposomes | 1 | 2006 | 107 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 700 | 0.020 |
Why?
|
| Contract Services | 1 | 1984 | 6 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2004 | 4 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 22 | 0.010 |
Why?
|
| Paracrine Communication | 1 | 2004 | 31 | 0.010 |
Why?
|
| Gels | 1 | 2004 | 55 | 0.010 |
Why?
|
| United Kingdom | 1 | 1984 | 152 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1991 | 3705 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2003 | 18 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 101 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 301 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 541 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1984 | 383 | 0.010 |
Why?
|
| Eye Diseases | 1 | 1982 | 38 | 0.010 |
Why?
|
| Optic Nerve Injuries | 1 | 1981 | 5 | 0.010 |
Why?
|
| Retinal Detachment | 1 | 1981 | 14 | 0.010 |
Why?
|
| Optic Nerve | 1 | 1982 | 55 | 0.010 |
Why?
|
| Eye Injuries | 1 | 1981 | 18 | 0.010 |
Why?
|
| Vision Tests | 2 | 1992 | 18 | 0.010 |
Why?
|
| Mathematics | 2 | 1991 | 83 | 0.010 |
Why?
|
| Reference Values | 1 | 1982 | 579 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1980 | 160 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 1752 | 0.010 |
Why?
|
| Methods | 1 | 1991 | 156 | 0.010 |
Why?
|
| Anthropometry | 1 | 1990 | 64 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1990 | 238 | 0.010 |
Why?
|
| Light | 1 | 1990 | 152 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1990 | 453 | 0.000 |
Why?
|